Short answer
Pfizer Inc (PFE) filed an 8-K current report with the SEC on June 18, 2026 reporting Item 7.01 (Regulation FD Disclosure). 2026 guidance reaffirmed after CFO transition, signaling no immediate change to operating or financial outlook.
Pfizer Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- 2026 guidance reaffirmed after CFO transition, signaling no immediate change to operating or financial outlook
- Revenue guidance maintained at $59.5–$62.5 billion
- Adjusted diluted EPS guidance maintained at $2.80–$3.00
- Key downside exposures include COVID-19 demand, drug pricing policy, tariffs, regulatory outcomes, pipeline execution and litigation
- Guidance remains forward-looking and subject to substantial uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pfizer Inc 8-K filings
Get the next PFE 8-K as it lands
Follow PFE for push alerts, or ask the research agent what this filing means.